Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04030429
Other study ID # B-BR-108-016
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2019
Est. completion date February 2024

Study information

Verified date April 2022
Source National Cheng-Kung University Hospital
Contact Keng-Fu Hsu, PhD
Phone +886-6-2353535
Email d5580@mail.ncku.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The majority of endometrial cancer patients with disease spread beyond the uterus will progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in metastatic or advanced endometrial cancer. There is no standard protocol for the second-line option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an approved drug for the treatment of ALK-positive non-small cell lung cancer, demonstrated activities in endometrial cancer with c-MET kinase and Sema domain mutations. As a consequence, a phase 2 clinical trial to investigate the efficacy of Crizotinib in endometrial cancer patients with MET mutation is initiated.


Description:

In this phase 2 study, the target population is patients with recurrent or persistent metastatic endometrial cancer. The mutation status of c-MET gene will be tested and only patients with c-MET mutation will be enrolled. After enrollment, Crizotinib 250 mg bid will be used orally. CT scan or MRI will be used to determine the response. Crizotinib will be continued till disease progression. Primary end is objective response rate. The secondary endpoints include progression-free survival, overall survival and safety profiles.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date February 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Age no less than 20 years and no more than 75 years, at the time of acquisition of informed consent. - Histological confirmed epithelial endometrial cancer - Disease recurrent after curative therapy or adjuvant therapy including surgery, chemotherapy, radiotherapy or hormone therapy - Metastatic/recurrent/persistent endometrial cancer - Tumor tissue with high expression in immunohistochemistry stain (IHC) or somatic c-MET mutation - Patients with symptomatic recurrent lesion or Image diagnosis (including ultrasound, Computed Tomography or Magnetic Resonance Imaging) recurrent status - ECOG Performance status 0-2 - At least one distinct tumor, not previous irradiated, measurable lesion according to RECIST (version 1.1) - Adequate organ function Bone marrow: Absolute neutrophil count (ANC) = 1.5 x 10^9/L WBC = 3.0 x 10^9/L Platelet count = 100 x 10^9/L Hemoglobin = 9 g/dL Hepatic: Total bilirubin level = 1.0 x UNL AST and ALT = 3.0 x UNL Renal: Creatinine level = 1.5 mg/dL in men, =1.4 mg/dL in women; or Estimated CCr = 60 mL/min (CCr is estimated by Cockcroft-Gault formula) - Negative pregnancy test for women of childbearing potential only - Patient willing to provide blood sample for research purposes - Written informed consent Exclusion Criteria: - Presence or history of malignancy disease other than endometrial cancer that has been diagnosed with past five years - Other anti-tumor agent such as systemic chemotherapy, hormone therapy or surgery within 2 weeks before the commencement of study treatment or radiotherapy within 4 weeks before the commencement of study - Active uncontrolled infection - Significant medical diseases, such as unstable angina, acute or recent myocardial infarction (<6 months before enrollment), COPD with frequent exacerbation, uncontrolled hypertension, ore cent CVA (<6 months before enrollment) - Poor compliance - Pregnant or breastfeeding women, where pregnancy is confirmed by a positive hCG laboratory test.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Crizotinib 250 MG
bid orally

Locations

Country Name City State
Taiwan National Cheng Kung University Hospital Tainan

Sponsors (4)

Lead Sponsor Collaborator
National Cheng-Kung University Hospital Chi Mei Medical Hospital, Kaohsiung Medical University, Kaohsiung Veterans General Hospital.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in best overall response rate CT scan or MRI will be used to evaluate the response every 2 cycles according to the RECIST 1.1 criteria. The best overall response rate is the proportion of patients in whom a complete response (CR) or partial response (PR) was observed. CT scan or MRI will be done at baseline and at the end of every 2 cycles (each cycle is 28 days) until the date of first documented progression or date of death from any cause, whichever came first, up to 104 weeks
Secondary Progression-free survival CT scan or MRI will be used to evaluate the response according to RECIST 1.1 criteria. Progression-free survival is defined as the time from the time of treatment to disease progression or death from any cause. CT scan or MRI will be done at baseline and at the end of every 2 cycles (each cycle is 28 days) until the date of first documented progression or date of death from any cause, whichever came first, up to 104 weeks
Secondary Overall survival Overall survival is defined as defined as the time from the start of treatment to death from any cause. Overall survival will be followed from the start of treatment to death from any cause, up to 104 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT03621904 - PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Active, not recruiting NCT03485729 - ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Phase 2
Recruiting NCT05410717 - CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors Phase 1
Completed NCT03015129 - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Phase 2